Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AIM Stock Forecast 2025-2026
$9.09
Current Price
$6.95M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AIM Price Targets
+1,550.2%
To High Target of $150.00
+1,550.2%
To Median Target of $150.00
+1,550.2%
To Low Target of $150.00
AIM Price Momentum
+2.7%
1 Week Change
+35.7%
1 Month Change
-75.4%
1 Year Change
-54.6%
Year-to-Date Change
-78.9%
From 52W High of $43.00
+203.0%
From 52W Low of $3.00
📊 TOP ANALYST CALLS
Did AIM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AIM ImmunoTech is one of their latest high-conviction picks.
Latest AIM Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AIM has a bullish consensus with a median price target of $150.00 (ranging from $150.00 to $150.00). Currently trading at $9.09, the median forecast implies a 1,550.2% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AIM Analyst Ratings
1
Buy
0
Hold
0
Sell
AIM Price Target Range
Low
$150.00
Average
$150.00
High
$150.00
Current: $9.09
Latest AIM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AIM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $4.50 |
| Oct 22, 2024 | Maxim Group | Buy | Maintains | $0.00 | |
| Sep 3, 2024 | Ascendiant Capital | Buy | Maintains | $0.00 | |
| Oct 10, 2019 | Maxim Group | Buy | Upgrade | $0.00 |
AIM ImmunoTech Inc. (AIM) Competitors
The following stocks are similar to AIM ImmunoTech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AIM ImmunoTech Inc. (AIM) Financial Data
AIM ImmunoTech Inc. has a market capitalization of $6.95M with a P/E ratio of -29.3x. The company generates $146,000 in trailing twelve-month revenue with a 81.8% profit margin.
Revenue growth is -60.0% quarter-over-quarter, while maintaining an operating margin of -22,618.8% and return on equity of -3,138.9%.
Valuation Metrics
Market Cap
$6.95M
Enterprise Value
$6.89M
P/E Ratio
-29.3x
PEG Ratio
0.0x
Price/Sales
47.6x
Growth & Margins
Revenue Growth (YoY)
-60.0%
Gross Margin
+37.5%
Operating Margin
-22,618.8%
Net Margin
+81.8%
EPS Growth
-60.0%
Financial Health
Cash/Price Ratio
+32.3%
Current Ratio
0.3x
Debt/Equity
-0.7x
ROE
-3,138.9%
ROA
-98.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AIM ImmunoTech Inc. (AIM) Business Model
About AIM ImmunoTech Inc.
What They Do
Biopharmaceutical company developing immunology-based therapeutics.
Business Model
AIM ImmunoTech focuses on the research and development of immunology-based therapeutics to address unmet medical needs, particularly in oncology and viral diseases. The company generates revenue through the commercialization of its products, which include Ampligen®, currently in clinical trials for various conditions, and Alferon N Injection®, approved for specific viral infections.
Additional Information
The company is based in Ocala, Florida, and collaborates with leading research institutions worldwide. AIM ImmunoTech is committed to advancing innovative immunotherapy solutions that leverage the body's immune response to tackle complex medical challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Country
United States
IPO Year
N/A
Website
aimimmuno.comAIM ImmunoTech Inc. (AIM) Latest News & Analysis
Latest News
Quick Summary
AIM ImmunoTech Inc. presented its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, featuring discussion by oncologist Pawel Kalinski on immunotherapy advancements.
Why It Matters
AIM ImmunoTech's presentation on Ampligen at a prestigious symposium highlights its potential in immunotherapy, possibly boosting investor confidence and interest in the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NYSE American has reiterated a warning regarding a deficiency, noting it remains unresolved as of March 31, 2025.
Why It Matters
The ongoing deficiency warning from NYSE American signals potential compliance issues, which could lead to delisting, affecting stock prices and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AIM ImmunoTech Resumes Trading on NYSE American
26 days ago
Quick Summary
The company will begin trading under the ticker "AIM" on NYSE American starting today, June 17th.
Why It Matters
The change to ticker "AIM" on NYSE American signals a new branding or strategic shift, potentially impacting investor perception and trading activity around the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AIM ImmunoTech Inc. will implement a 1-for-100 reverse stock split effective June 12, 2025. The ticker symbol will be AIMID on OTC Pink for 20 trading days post-split.
Why It Matters
A reverse stock split can indicate attempts to boost share price and maintain compliance with listing standards, affecting liquidity and investor perception of AIM ImmunoTech's stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company is set to resume trading on the NYSE American on June 17, 2025.
Why It Matters
The company's resumption of trading signals potential recovery and renewed investor interest, impacting stock liquidity and valuation prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
1 month ago
Quick Summary
AIM ImmunoTech Inc. has secured a U.S. patent for the manufacturing methods and compositions of Ampligen, extending protection until 2041.
Why It Matters
AIM ImmunoTech's patent protection until 2041 enhances its competitive position and potential revenue, signaling long-term value and stability for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AIM Stock
What is AIM ImmunoTech Inc.'s (AIM) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, AIM ImmunoTech Inc. (AIM) has a median price target of $150.00. The highest price target is $150.00 and the lowest is $150.00.
Is AIM stock a good investment in 2026?
According to current analyst ratings, AIM has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AIM stock?
Wall Street analysts predict AIM stock could reach $150.00 in the next 12 months. This represents a 1,550.2% increase from the current price of $9.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AIM ImmunoTech Inc.'s business model?
AIM ImmunoTech focuses on the research and development of immunology-based therapeutics to address unmet medical needs, particularly in oncology and viral diseases. The company generates revenue through the commercialization of its products, which include Ampligen®, currently in clinical trials for various conditions, and Alferon N Injection®, approved for specific viral infections.
What is the highest forecasted price for AIM AIM ImmunoTech Inc.?
The highest price target for AIM is $150.00 from at , which represents a 1,550.2% increase from the current price of $9.09.
What is the lowest forecasted price for AIM AIM ImmunoTech Inc.?
The lowest price target for AIM is $150.00 from at , which represents a 1,550.2% increase from the current price of $9.09.
What is the overall AIM consensus from analysts for AIM ImmunoTech Inc.?
The overall analyst consensus for AIM is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $150.00.
How accurate are AIM stock price projections?
Stock price projections, including those for AIM ImmunoTech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 8:13 PM UTC